Calidi Biotherapeutics Announces Chief Executive Officer Transition and Appointment of Eric Poma, Ph.D. as CEO and Director
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 23 2025
0mins
Source: Globenewswire
Leadership Transition: Calidi Biotherapeutics has appointed Eric Poma, Ph.D., as the new CEO, succeeding Allan Camaisa, who will remain on the Board of Directors. Dr. Poma brings over 30 years of experience in the biopharmaceutical industry, particularly in oncology.
Company Focus: Calidi is advancing its systemic enveloped virotherapy platform and preparing for clinical trials of its therapeutic candidates, aiming to enhance cancer treatment efficacy and patient safety through innovative technologies.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
